Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

675
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
675
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

643
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
643
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.8K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

566
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
566

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model.

Clinical science (London, England : 1979)·2026
Same author

Vascular Aging.

Circulation·2026
Same author

Astrocytic frataxin deficiency drives neurocognitive impairment in sickle cell mice.

PNAS nexus·2026
Same author

FOSL2 regulates endothelial cell state and chromatin accessibility in systemic sclerosis pulmonary vascular remodeling.

JCI insight·2026
Same author

MCT4 mediates hypoxia-induced extracellular lactate release from IPF fibroblasts.

American journal of respiratory cell and molecular biology·2026
Same author

Health outcomes after national acute sleep deprivation events among the American public.

JCI insight·2025

Related Experiment Video

Updated: Feb 16, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K

Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.

Stephen Y Chan1, Lewis J Rubin2

  • 1Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA chansy@pitt.edu.

European Respiratory Review : an Official Journal of the European Respiratory Society
|December 22, 2017
PubMed
Summary
This summary is machine-generated.

Pulmonary hypertension (PH) involves metabolic changes in blood vessels and the heart. Targeting these metabolic pathways offers new diagnostic and treatment strategies for this serious vascular disease.

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

817
Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model
07:10

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Published on: June 3, 2020

10.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.6K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

817
Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model
07:10

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Published on: June 3, 2020

10.8K

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disease
  • Pulmonary Vascular Biology

Background:

  • Pulmonary hypertension (PH) is a fatal vascular disease with unknown molecular causes.
  • PH involves pulmonary vascular remodeling, increased vasomotor tone, and a pro-proliferative state, leading to right ventricular dysfunction.
  • Metabolic changes in pulmonary vessels and the right ventricle are increasingly recognized as key factors in PH pathogenesis.

Purpose of the Study:

  • To review the dysregulated metabolic mechanisms in PH.
  • To explore advanced diagnostic and imaging techniques for PH.
  • To discuss novel therapeutic drugs targeting metabolic pathways in PH.

Main Methods:

  • Literature review of metabolic aberrations in pulmonary hypertension.
  • Analysis of current and emerging diagnostic and imaging modalities.
  • Survey of new drugs targeting metabolic pathways for PH treatment.

Main Results:

  • Metabolic dysregulation is a critical component of PH pathophysiology.
  • Advancements in diagnostic testing and imaging are improving PH detection.
  • Emerging therapies targeting metabolic pathways show promise for PH management.

Conclusions:

  • Metabolic pathways are central to PH development and progression.
  • Targeting metabolic aberrations offers a promising strategy for PH diagnosis and treatment.
  • Further research into metabolic interventions could lead to improved outcomes for PH patients.